Guardant Health and Zydus Lifesciences have partnered to introduce a transformative multi-cancer detection test in India. This innovative tool aims to address the rising cancer burden through early detection. Moreover, the liquid biopsy technology identifies tumor DNA fragments in the blood. Therefore, it provides a minimally invasive alternative to traditional tissue-based diagnostic procedures.

The Clinical Utility of Multi-cancer Detection Test Technology

The 'Shield' test recently received FDA approval in the United States for colorectal cancer screening. However, the Indian rollout will cover a broader panel including lung, breast, and gastric cancers. Clinical data indicates that the test has an 83% sensitivity for colorectal cancer. Furthermore, it detects approximately 100% of stage II to IV colorectal malignancies. Consequently, clinicians can utilize this blood-based screening to identify tumors before symptoms appear.

Addressing Diagnostic Gaps in the Indian Market

India currently reports that nearly 70% of cancer cases are diagnosed at advanced stages. This delay often leads to poorer clinical outcomes and significantly higher treatment expenses. Additionally, screening rates for common cancers remain exceptionally low across the country. Guardant Health is currently negotiating with ten major hospital chains and wellness centers for the rollout. Although the US price is around Rs 1.4 lakh, local pricing is being carefully developed with Zydus.

Future Outlook for Precision Oncology

Early detection through genomic profiling could improve survival rates by up to ten times. By identifying mutations through simple blood draws, healthcare providers can personalize treatment paths earlier. Finally, the collaboration between Guardant and Zydus represents a strategic shift toward preventive oncology in India.

Frequently Asked Questions

Q1: Which specific cancers can the multi-cancer detection test identify?

The panel includes gastric, esophageal, liver, colorectal, ovarian, lung, pancreatic, bladder, breast, and prostate cancers.

Q2: Is this blood test a replacement for a traditional colonoscopy?

No, it is a screening tool. Patients who receive a positive result from the blood test must follow up with a diagnostic colonoscopy for confirmation.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Guardant Health to launch blood-based cancer test in India with ZydusLifesciences - ETHealthworld


2. Shield™ Colorectal Cancer Screening Blood Test - Guardant Health Official Site


3. FDA Approves Blood Test for Colorectal Cancer Screening - National Cancer Institute